Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAMBRIA-2: Camizestrant vs Standard Endocrine Therapy in ER+/HER2- Early Breast Cancer
NCT05952557Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2023
- Primary completion
- Mar 2030
- Modality
- Small Molecules
- Countries
- 44
01
Overview
Phase 3, randomised, open-label trial of camizestrant in breast cancer (2 arms), sponsored by AstraZeneca. Primary endpoint: Invasive breast cancer-free survival up to 14 years. Started Oct 2023; status: active, not recruiting.
02
Drugs
camizestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05952557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05952557.